Characteristics of Real-World Patients with High-Risk <em>BRAF</em><sup>V600E/K</sup>-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Original Research

Characteristics of Real-World Patients with High-Risk BRAF^V600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Total article views		HTML views	PDF downloads	Totals
2,901	Dovepress*	2,779+	104	2,883
	PubMed Central*	122	68	190
	Totals	2,901	172	3,073
*Since 11 November 2023

Total mentioned	Facebook	Delicious	Reddit	Twitter	Others
2	0	0	0	1	1